if we do not translate all of those findings that occur at the pharmaceutical level at the university level into healthcare products which are affordable and that treat disease and that curious them and as long as we do not understand disease and their causes and how to treat or cure them, there is no point really in talking about the solution of healthcare problem. because health insurance coverage is going to provide health insurance. but when it comes to drugs, when it comes to the premiums and subsidies where are these subsidies going to come from? from taxpayer money. it's not people are going to get the dollars out of the trees. people have to pay for that. and there is a limit. economy is the science of limitations. so we don't deal with a better system of working on prevention and working on understanding, how we could take care of our own health, then there is no point in having health insurance. what is going to happen is what happens in columbia now. everything can have access to healthcare. what happens in europe too, in which people are covered but when it comes to the me

the issue of innovation, if we do not translate all those findings that occur at the pharmaceutical university level into health care products which are affordable and treat disease and cures them, as long as we do not understand -- how to treat or cure them, there is no point in talking about the solution of the health care problem. because health insurance what is going to provide health insurance. when it comes to the premiums, when it comes to subsidies, where are the subsidies going to come from? from taxpayers. it is not the people look at the dollars out of the trees. no. people have to pay for that. and there is a limit. the economy is basically the science of limitations. a if we don't deal with better system of working on prevention, working on understanding, how we can take care of our own health, then there is no point in just having health insurance because what is going to happen is what happens in columbia. is people are covered. what happens in panama. everybody can have access to health care. but what happens in europe, too, which people are covered but when it comes to medications

of innovation, if we do not translate all of those bindings that occur at the pharmaceutical industry at the university level into health care programs which are affordable and treat disease and cures them and as long as we do not understand their causes and how to treat or cure them there is no point really in talking about the solution of the health care problem. because health insurance coverage is what is going to provide health insurance but when it comes to drugs, when it comes to the premiums when it comes to subsidies where the subsidies going to come from? from taxpayers money. people are not going to get the dollars out of the trees. people have to pay for that. the economy is basically the science of limitations so if we don't deal with a better system on working with understanding and how we can take care of our own health there is no point in having health insurance. what is going to happen is what is happening in colombia right now. everybody can have access to health care but what happens in europe in which people are covered when it comes to medications and when it comes to drugs than governm

. >> we have large cap pharmaceuticals that are no longer doing the level of r & d like they're goinghese comes uspanies used to ge bought before they went public. but the market, as stephanie said, will sort it out over time. >> here's a shocker. you guys voted. that's not a shocker. results, not a shocker either. stephanie link won the debate on hp. it was a kind of foregone conclusion after you -- you basically said you made a lame argument, right? >> didn't make a lame argument. made an excellent argument. i made a mistake. any good trader admits his mistake immediately. i did that. >> if you make a mistake in your closing argument, chances are the jury's not going to go with you, right? so that's what happened. we can go in the chambers and talk about it after the show. >> that's just game theory, joe. >> final trade what do you like? >> m & t bank. >> joe? >> how about yelp, long. >> josh. >> mastercard, buy. >> have a great rest of the day. "power" starts here. >> announcer: halftime's over. the second half of your trading day begins now. >> scott, folks, thank you very much. f

of innovation, if we do not translate all of those findings that occur at the pharmaceutical industry, at the university level, into health care products which are affordable and treat disease enters them, -- and nots them, as long as we do do that there is no point in talking about the solution of the health care problem. islth insurance coverage going to provide health insurance, but when it comes to drugs, when it comes to the premiums, when it comes to subsidies, where are the subsidies going to come from? taxpayers' money. it is not the people get dollars out of the trees. people have to pay for that and there is a limit. the economy is basically the sign -- science of limitations. if we don't deal with a better system about working on prevention, working on understanding how we could take care of our own health, then there is no point in just having health insurance because what is going to happen? -- inappens incolobm colombia right now. it happens in europe as well. toy're covered when it comes drugs, but governments are having problems affording every -- affording them. >> the future of drugs. >> hou

sales of pharmaceuticals have gone up like wildfire. recently they've leveled off, and i'll come back to that in a minute to talk about the government's role there. what does this have to do with regula tour programs? first, patents. it actually outlaws the free market, it restrains who can offer a product. it's the bedrock foundation of the pharmaceutical industry as any executive in the industry will tell you. it is this program that headaches the whole -- makes the whole business model of pharmaceuticals possible. beyond that we have the fda which instills customer confidence that the drugs we take aren't going to kill us and competence in the physicians who prescribe the drug that they're not going to lose their patients. first law was in 1906. a new drug law announced with a lot of fanfare. it meant that we didn't have a number of products like this ad for cocaine toothpaste drops. maybe we'd be better off with them, but the fda made sure that drugs that were considered up safe were kept away from us. in 1938 the law was substantially expanded after a scan

>> under french national health insurance, there's very high levels of pharmaceutical coverage. >> meaningwhat? my medicine is free or virtually free? >> virtually free. 90%, 80%, 70%. >> dr. martin? >> those prescription drugs are cut because they're ineffective. >> dr. martin? >> interestingly, this is an area where we made a mistake in the design of our single-payer program in canada at the time. canadian medicare was designed in the 1950s, and '60s. medication was not a really big part of the way that we treated disease, and medicines were left out of coverage. so the single-payer program in canada does not include medication, and as a result, 1 in 10 canadians today fails to pill a prescription or take their medicine as prescribed because of concerns about cost. >> thank you. mr. kjellberg? what about prescription drugs in denmark? >> all hospital use at hospital are prix of charge. and if -- free of charge. and if prescription drugs are needed, you have a maximum co-payment a year about $600. >> okay. dr. yeh? in taiwan, how much do prescription drugs cost? >> it is covered by the --

of know vision, if we do not translate all those findings that occur at the pharmaceutical industry, at the university levelinto health care products which affordable and treat disease and that cures them and as long as we do not understand the disease, the causes and how to treat or cure them, there is no point really in talking about the solution of the health care problem because health insurance cover us, it is, what is going to provide health insurance but when it comes to drugs, when it comes to premiums, when it comes to subsidies, where are the subsidies going to come from? no taxpayer's money. not just that people will get dollars out of the trees. no, people have to pay for that. there is a limit. the economy is basically the science of limitations. so if we don't deal with a better system of working on prevention, of working on understanding, how we could take care of our own health then there is no point just having health insurance because, what is going to happen what happens in colombia right now which people are covered. like what happens in panama. everybody can have access to health care.

pharmaceuticals. but if there are things we can do at the state level, i'm all ears. and i think it's going to take a bigger push. that's something that probably can happen at the federal level. there can be more incentives built in, more tax incentives for the development of pharmaceuticals. >> what about the insurance side of things? the mental health parity act was passed some years ago and now, of course, today is the obamacare sign-up deadline. do you think that there is enough access to parity for mental health treatment this our insurance m now -- in our insurance system now? >> i don't think there's enough access to parity in the mental health. you know, one of the significant achievement. s of the affordable care act is that there is parity, you know? for instance, if we pass a form of medicaid expansion in virginia, that would immediately open up about $200 million a year for people that are mentally ill. people that are in that phase of medicaid expansion would have better access to mental health care than a whole lot of other people that have health insura

pharmaceutical business to focus on the overseas markets. within the first year after the spinoff the chinese authorities leveled some dubious charges of price fixing and raised quality concerns about the infant formula being sold by overseas suppliers and suddenly that growth came to a halt. now that will be temporary but that's not in the plan. in the meantime its business in the u.s. has been tanking. >>now they learned they can play both markets but you have to know what you're doing. joethanks so much. coming up...russia's meddling in ukraine has created hot stocks in energy that may be good buys with potential gains. we'll learn more in chart talk. and after the break, thel latest in household appliances - we head to the housewares show with chuck coppola! homebuilders can't seem to shake the winter blues. a gauge of their confidence ticked up a point to 47. anything under 50 on the home builders - wells fargo housing market index is interpreted as pessimistic. it's the weather. it's making it hard to find lots and labor to get projects started. the worst region for home construction right now - the north east - which happens to be the

level. there could be more incentives built in for the development of pharmaceuticals. >> what about the insurancee of things? the mental health parity act was passed a few years ago and now today is the obamacare sign-up deadline. do you think there is enough access to parity for mental health treatment and -- in earn certain system now -- in our insurance system now? >> i don't think so. one of the afford -- achievement of the affordable care act is there is parity. a form of medicaid expansion in virginia, that would immediately open up about $200 million a year for people that are mentally ill. people that are in that stage of medicaid expansion would have better access to mental health care. we don't have enough equity. the problem with the parity law is that it has not brought about parity. the affordable care act does so that is significant. [applause] >> we have a couple of questions about veterans. we've had some speakers here at the press club talk about veterans need primitive of care. -- need for mental health care. do you think that is something that should be done in the efforts you'

an innovation and we do not translate all the findings that occur at these pharmaceutical industries and at the university levelhealth care products that are affordable and vacherie disease and that cure them. as long as we do not understand how to treat and cure diseases, there is no point in talking about the solution to the health care problem. when it comes to drugs, when it comes to the premiums, when it comes to subsidies, where are the subsidies going to come from? from taxpayer money. it is not that people are going to get a dollars out of the trees, people had to pay for that and there is a limit. the economy is basically the science of limitations. deal with a better system of working on prevention and working on understanding how we can take care of our health, there is no point in having health insurance. what is going to happen is what is happening in colombia right now. everybody can have access to health care. what happens in europe, too. people are covered but when it comes to medication and access to drugs, the government are having problems affording them. >> the future of health care, sunday

level without your equipment, can they? >> no, i mean, we are the key supplier. >> right. >> the largest supplier by for to biotech and pharmaceuticales and they do incredible work. if they are trying to cure cancer and fight the right drug, they will use our products to do the scientific discoveries and used for dna sequencing and protein research, very core to those scientific efforts. >> now you also have what people should understand as being the essential raiser blade business. please explain to people why you have this stream? >> yeah, so today 25% of our revenue is instrumentation and equipment and the aftermarket, consumables, chemicals and services we have which headaches the business predictable, stable and growing over time. >> let's be sure because one came out recently and saying there are worries about academic funding. thee these are not worries for funding. >> it was a head wind for our industry, but we continued to gain market share and with a budget deal in the u.s., that's a positive. we see the economic and government improving and getting back to better growth. >> i look at the european commission is doing. you

pharmaceutical company has been cut, it's rating was cut -- its rating was cut. however goldman did keep its 84 dollar price target, which is above where the stock is trading now. that levelbe the average price target by analysts survived by bloomberg. also abby. this rug maker being sued by gilead. -- drug maker being sued by gilead. broadly is thee focus of the sector report today. i object is teetering on correction. off thisarly 14% year's five. i am joined i michael reagan. this is a group that had done incredibly well. all of a sudden, people seem to be debating a bubble. was there some sort of catalyst? what changed? >> the started at the end of february, beginning of march. that is where the stock started to weaken, not just tesla,eutical, but netflix, google. the etf was down six percent from the end of february through last thursday. then lawmakers and house democrat in washington added fuel to the fire by questioning gilead about its hepatitis c costs $84,000 and sending them a letter and saying, why does this cost them much? spooked out the biotech investors. little changed today, but really a sharp correction. >> and gilead is a relatively large company. for

level it's currently trading. you can see there, just about 1873. leading the index higher, micron followed by edward life sciences, cigna, vertex pharmaceuticals andlcoa. those shares helping to try to push to that new record high. >> thank you again for the dayton flyers last week. they gave a good fight in the tournament. thank you. >>> in the midst of joint military exercises involving the u.s. and south korea, the north took things a step further. north korea firing more than 100 artillery rounds into south korean waters as part of a drill. that led to south korea firing back. the south koreans near the border were forced into bomb shelters as a result of this. nobody was hurt but you can see there was a lot of smoke and action. sue? >> tensions are rising in that part of the world. the markets paying attention to that, too. >>> also, look at this. two back-to-back earthquakes hitting southern california. los angeles shaken by nearly 175 smaller aftershocks. there has been damage but will earthquake insurance actually cover it? our jane wells is in fullerton, california, just about five miles from the epicenter. jane, over to you. >> reporter: